 |  |  |
|  |
|
| |||||||||||||||||||||||||||||||
|
|
| | |||||||
|
| 1. | Title: The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines
Author(s): Papageorgiou E, Pitulis N, Msaouel P, et al. Source: EXPERT OPINION ON THERAPEUTIC TARGETS Volume: 11 Issue: 8 Pages: 1071-1085 Published: AUG 2007 |
| 2. | Title: Therapeutic potential of thiazolidinediones as anticancer agents
Author(s): Panigrahy D, Shen LQ, Kieran MW, et al. Source: EXPERT OPINION ON INVESTIGATIONAL DRUGS Volume: 12 Issue: 12 Pages: 1925-1937 Published: DEC 2003 |
| 3. | Title: Present concepts and outlook: Function of proliferator-activated receptors (PPARs) for future peroxisome pathogenesis, progression, and therapy of cancer
Author(s): Sertznig P, Seifert M, Tilgen W, et al. Source: JOURNAL OF CELLULAR PHYSIOLOGY Volume: 212 Issue: 1 Pages: 1-12 Published: JUL 2007 |
| 4. | Title: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
Author(s): Grommes C, Landreth GE, Heneka MT Source: LANCET ONCOLOGY Volume: 5 Issue: 7 Pages: 419-429 Published: JUL 2004 |
| 5. | Title: Peroxisome proliferator-activated receptor-gamma in lung cancer: Defining specific versus "off-target" effectors
Author(s): Nemenoff RA Source: JOURNAL OF THORACIC ONCOLOGY Volume: 2 Issue: 11 Pages: 989-992 Published: NOV 2007 |
| 6. | Title: Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease
Author(s): Varani J, Bhagavathula N, Ellis CN, et al. Source: EXPERT OPINION ON INVESTIGATIONAL DRUGS Volume: 15 Issue: 11 Pages: 1453-1468 Published: NOV 2006 |
| 7. | Title: Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: An example of nongenomic signaling
Author(s): Gardner OS, Dewar BJ, Graves LM Source: MOLECULAR PHARMACOLOGY Volume: 68 Issue: 4 Pages: 933-941 Published: OCT 2005 |
| 8. | Title: New indications for established drugs: Combined tumor-stroma-targeted cancer therapy with PPAR gamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy
Author(s): Hafner C, Reichle A, Vogt T Source: CURRENT CANCER DRUG TARGETS Volume: 5 Issue: 6 Pages: 393-419 Published: SEP 2005 |
| 9. | Title: Crosstalk of oncogenic and prostanoid signaling pathways
Author(s): Muller R Source: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Volume: 130 Issue: 8 Pages: 429-444 Published: AUG 2004 |
| 10. | Title: Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma - A novel mechanism for its anti-tumorigenic activity
Author(s): Baek SJ, Wilson LC, Hsi LC, et al. Source: JOURNAL OF BIOLOGICAL CHEMISTRY Volume: 278 Issue: 8 Pages: 5845-5853 Published: FEB 21 2003 |
|  |
